دورية أكاديمية
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades
| العنوان: | Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades |
|---|---|
| المؤلفون: | Jason P. Cooper, Barry E. Storer, Noa Granot, Boglark Gyurkocza, Mohamed L. Sorror, Thomas R. Chauncey, Judith Shizuru, Georg-Nikolaus Franke, Michael B. Maris, Michael Boyer, Benedetto Bruno, Firoozeh Sahebi, Amelia A. Langston, Parameswaran Hari, Edward D. Agura, Søren Lykke Petersen, Richard T. Maziarz, Wolfgang Bethge, Julie Asch, Jonathan A. Gutman, Gitte Olesen, Andrew M. Yeager, Kai Hübel, William J. Hogan, David G. Maloney, Marco Mielcarek, Paul J. Martin, Mary E.D. Flowers, George E. Georges, Ann E. Woolfrey, H. Joachim Deeg, Bart L. Scott, George B. McDonald, Rainer Storb, Brenda M. Sandmaier |
| المصدر: | Haematologica, Vol 106, Iss 6 (2020) |
| بيانات النشر: | Ferrata Storti Foundation, 2020. |
| سنة النشر: | 2020 |
| المجموعة: | LCC:Diseases of the blood and blood-forming organs |
| مصطلحات موضوعية: | Diseases of the blood and blood-forming organs, RC633-647.5 |
| الوصف: | We have used a non-myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation for the past twenty years. During that period, changes in clinical practice have been aimed at reducing morbidity and mortality from infections, organ toxicity, and graft-versus-host disease. We hypothesized that improvements in clinical practice led to better transplantation outcomes over time. From 1997-2017, 1,720 patients with hematologic malignancies received low-dose total body irradiation +/- fludarabine or clofarabine before transplantation from HLA-matched sibling or unrelated donors, followed by mycophenolate mofetil and a calcineurin inhibitor ± sirolimus. We compared outcomes in three cohorts by year of transplantation: 1997 +/- 2003 (n=562), 2004 +/- 2009 (n=594), and 2010 +/- 2017 (n=564). The proportion of patients ≥60 years old increased from 27% in 1997 +/- 2003 to 56% in 2010–2017, and with scores from the Hematopoietic Cell Transplantation Comborbidity Index of ≥3 increased from 25% in 1997 +/- 2003 to 45% in 2010 +/- 2017. Use of unrelated donors increased from 34% in 1997 +/- 2003 to 65% in 2010–2017. When outcomes from 2004 +/- 2009 and 2010–2017 were compared to 1997 +/- 2003, improvements were noted in overall survival (P=.0001 for 2004–2009 and P |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 0390-6078 1592-8721 |
| Relation: | https://haematologica.org/article/view/9770; https://doaj.org/toc/0390-6078; https://doaj.org/toc/1592-8721 |
| DOI: | 10.3324/haematol.2020.248187 |
| URL الوصول: | https://doaj.org/article/b53a5c54d0c946cb9309c9ef5ead75fa |
| رقم الأكسشن: | edsdoj.b53a5c54d0c946cb9309c9ef5ead75fa |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 03906078 15928721 |
|---|---|
| DOI: | 10.3324/haematol.2020.248187 |